In summary, our study established three key advances in TP53mutant NSCLC therapy: First, RG7388 induced dual-phase cell death through sequential apoptosis and pyroptosis, mediated by the ROS/p-p38/NOXA/caspase-3/GSDME axis. The gene discussed is PMAIP1; the disease is non-small cell lung carcinoma.